The estimated Net Worth of John P Brancaccio is at least $112 millier dollars as of 22 March 2021. Mr. Brancaccio owns over 3,000 units of Hepion Pharmaceuticals Inc stock worth over $9,195 and over the last 13 years he sold HEPA stock worth over $0. In addition, he makes $103,211 as Independent Director at Hepion Pharmaceuticals Inc.
Sign up
Mr. Brancaccio HEPA stock SEC Form 4 insiders trading
John has made over 11 trades of the Hepion Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of HEPA stock worth $32,850 on 22 March 2021.
The largest trade he's ever made was exercising 50,023 units of Hepion Pharmaceuticals Inc stock on 4 July 2018 worth over $25,012. On average, John trades about 4,141 units every 63 days since 2012. As of 22 March 2021 he still owns at least 12,260 units of Hepion Pharmaceuticals Inc stock.
You can see the complete history of Mr. Brancaccio stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Brancaccio biography
John P. Brancaccio CPA serves as Independent Director of the Company. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from April 2004 until May 2017. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. Mr. Brancaccio is currently a director of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) as well as a director of Cardiff Oncology, Inc. and Rasna Therapeutics, Inc., a biotechnology company. Mr. Brancaccio’s chief financial officer experience provides him with valuable financial and accounting expertise which the Board believes qualifies him to serve as a director of our Company.
What is the salary of John Brancaccio?
As the Independent Director of Hepion Pharmaceuticals Inc, the total compensation of John Brancaccio at Hepion Pharmaceuticals Inc is $103,211. There are 5 executives at Hepion Pharmaceuticals Inc getting paid more, with Robert Foster having the highest compensation of $621,102.
How old is John Brancaccio?
John Brancaccio is 71, he's been the Independent Director of Hepion Pharmaceuticals Inc since 2013. There are 4 older and 7 younger executives at Hepion Pharmaceuticals Inc. The oldest executive at Hepion Pharmaceuticals Inc is Thomas Adams, 77, who is the Independent Director.
What's John Brancaccio's mailing address?
John's mailing address filed with the SEC is C/O HEPION PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON, NJ, 08837.
Insiders trading at Hepion Pharmaceuticals Inc
Over the last 5 years, insiders at Hepion Pharmaceuticals Inc have traded over $0 worth of Hepion Pharmaceuticals Inc stock and bought 119,700 units worth $247,400 . The most active insiders traders include Gary S Jacob, Peter Wijngaard et John P Brancaccio. On average, Hepion Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $7,481. The most recent stock trade was executed by Peter Wijngaard on 24 November 2023, trading 5,000 units of HEPA stock currently worth $15,350.
What does Hepion Pharmaceuticals Inc do?
hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.
What does Hepion Pharmaceuticals Inc's logo look like?
Complete history of Mr. Brancaccio stock trades at Hepion Pharmaceuticals Inc et Cardiff Oncology
Hepion Pharmaceuticals Inc executives and stock owners
Hepion Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Robert Foster,
Chief Executive Officer, Chief Scientific Officer, Director -
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.,
Pres, CEO & Director -
Dr. Robert T. Foster B.Sc., BSc (Pharm), Pharm.D., Ph.D.,
Pres, CEO & Director -
John T. Cavan,
Chief Financial Officer -
John Cavan,
Chief Financial Officer -
John Brancaccio,
Independent Director -
Timothy Block,
Independent Director -
Arnold Lippa,
Independent Director -
Thomas Adams,
Independent Director -
Gary Jacob,
Chairman of the Board -
Stephen Kilmer,
IR Contact Officer -
Peter Wijngaard,
Independent Director -
Dr. Stephen A. Harrison,
Member of Scientific Advisory Board & Consultant Medical Director -
Dr. John Z. Sullivan-Bolyai,
Part-Time Consultant -
Dr. Todd M. Hobbs M.D.,
Chief Medical Officer -
Dr. Patrick Mayo Ph.D.,
Sr. VP of Clinical Pharmacology -
Dr. Daniel Trepanier Ph.D.,
Sr. VP of Drug Devel. -
Sharen Pyatetskaya,
Director of Investor Relations -
Dr. Daren Ure Ph.D.,
Chief Scientific Officer -
Michael J. Purcell,
Director -
Kaouthar Lbiati,
Director